# PK of Efavirenz & Lopinavir Nano-formulations in Healthy Volunteers

> **NCT02631473** · PHASE1 · SUSPENDED · sponsor: **St Stephens Aids Trust** · enrollment: 50 (estimated)

## Conditions studied

- HIV

## Interventions

- **DRUG:** 50mg NANO-efavirenz
- **DRUG:** 400mg NANO-Lopinavir
- **DRUG:** 200mg NANO-Lopinavir
- **DRUG:** 100mg Ritonavir
- **DRUG:** 300mg NANO-Efavirenz
- **DRUG:** 600mg Sustiva
- **DRUG:** 200mg NANO-Efavirenz
- **DRUG:** Kaletra® (lopinavir 400mg/ritonavir 100mg)
- **DRUG:** +/- 200mg NANO-Lopinavir
- **DRUG:** +/- 200mg ritonavir NORVIR
- **DRUG:** 400mg Sustiva

## Key facts

- **NCT ID:** NCT02631473
- **Lead sponsor:** St Stephens Aids Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2015-11
- **Primary completion:** 2017-11
- **Final completion:** —
- **Target enrollment:** 50 (ESTIMATED)
- **Why stopped:** Study is on hold whilst a grant application for further funding is put together
- **Last updated:** 2016-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02631473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02631473, "PK of Efavirenz & Lopinavir Nano-formulations in Healthy Volunteers". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02631473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*